Issues
-
Cover Image
Cover Image
Capsaicin is a principal pungent ingredient in hot peppers, which are consumed worldwide. Capsaicin has been shown to induce cancer cell death, and it has also been suggested that capsaicin may act as a carcinogen or cocarcinogen during the promotion stage of cancer. Hwang and colleagues show that capsaicin has a cocarcinogenic effect on TPA-promoted skin carcinogenesis in vivo that is mediated through the epidermal growth factor receptor (EGFR) and not the transient receptor potential vanilloid subfamily member 1 (TRPV1). Significantly, topical application of capsaicin on the dorsal skin of wild-type or TRPV1 knockout mice induced more and larger skin tumors in the knockout mice, suggesting that capsaicin acts through a TRPV1-independent mechanism. Notably, cyclooxygenase-2 (COX-2) expression was highly elevated with capsaicin treatment in TRPV1 knockout mice, and inhibitors of EGFR/MEK signaling suppressed capsaicin/TPA–induced COX-2 expression. These results raise concerns that a natural compound found in hot peppers used in over-the-counter topical pain remedies may heighten skin cancer risk by affecting EGFR-dependent signaling. For details, see the article by Hwang and colleagues on page 6859 of this issue. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Breaking Advances
Reviews
Priority Report
Integrated Systems and Technologies
Microenvironment and Immunology
Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Molecular and Cellular Pathobiology
Spi-1/PU.1 Oncogene Accelerates DNA Replication Fork Elongation and Promotes Genetic Instability in the Absence of DNA Breakage
Prevention and Epidemiology
Human Chorionic Gonadotropin in Pregnancy and Maternal Risk of Breast Cancer
Therapeutics, Targets, and Chemical Biology
SG2285, a Novel C2-Aryl-Substituted Pyrrolobenzodiazepine Dimer Prodrug That Cross-links DNA and Exerts Highly Potent Antitumor Activity
MET Kinase Inhibitor SGX523 Synergizes with Epidermal Growth Factor Receptor Inhibitor Erlotinib in a Hepatocyte Growth Factor–Dependent Fashion to Suppress Carcinoma Growth
Development of a Novel Tumor-Targeted Vascular Disrupting Agent Activated by Membrane-Type Matrix Metalloproteinases
Tumor and Stem Cell Biology
Voltage-Gated Na+ Channel SCN5A Is a Key Regulator of a Gene Transcriptional Network That Controls Colon Cancer Invasion
Matrix Metalloproteinase-9 Is Upregulated in Nucleophosmin-Anaplastic Lymphoma Kinase–Positive Anaplastic Lymphomas and Activated at the Cell Surface by the Chaperone Heat Shock Protein 90 to Promote Cell Invasion
Letters to the Editor
Correction
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.